GSK

GSK
D

GSK

Arincen73/100B

GSK net income 1985–2026

GSK earned 1.53B GBP in Q3 FY2026, the three months to 30 September 2026, down 24.0% on the same quarter a year before. GSK's net income over the last twelve months was 4.34B GBP, down 21.0% on the twelve months before. In fiscal year 2025 it earned 5.72B GBP, up 122.0% on the year before.

Last updated 7 Nov 2026 · Next report 3 Feb 2027

Net income

Net income · -3.8% a year over 10 yearsNet margin

Growth

Fiscal yearPeriod endingNet incomeGrowthNet marginRevenue
TTM30 Sept 20264.34B-21.03%12.96%33.47B
FY202531 Dec 20255.72B+121.98%17.50%32.67B
FY202431 Dec 20242.58B-47.75%8.21%31.38B
FY202331 Dec 20234.93B-67.05%16.25%30.33B
FY202231 Dec 202214.96B+241.07%51.00%29.32B
FY202131 Dec 20214.39B-23.73%17.76%24.70B
FY202031 Dec 20205.75B+23.77%23.61%24.35B
FY201931 Dec 20194.65B+28.21%13.76%33.75B
FY201831 Dec 20183.62B+136.49%11.75%30.82B
FY201731 Dec 20171.53B+67.98%5.08%30.19B
FY201631 Dec 2016912.00M-89.17%3.27%27.89B
FY201531 Dec 20158.42B+205.59%35.20%23.92B
FY201431 Dec 20142.76B-49.30%11.98%23.01B
FY201331 Dec 20135.44B+20.83%20.51%26.51B
FY201231 Dec 20124.50B-14.48%17.02%26.43B
FY201131 Dec 20115.26B+221.97%19.21%27.39B
FY201031 Dec 20101.63B-70.46%5.76%28.39B
FY200931 Dec 20095.53B+20.19%19.50%28.37B
FY200831 Dec 20084.60B-11.83%18.90%24.35B
FY200731 Dec 20075.22B-3.12%22.95%22.74B
FY200631 Dec 20065.39B+14.93%23.20%23.22B
FY200531 Dec 20054.69B+20.01%21.65%21.66B
FY200431 Dec 20043.91B-12.78%19.55%19.98B
FY200331 Dec 20034.48B+13.81%20.91%21.41B
FY200231 Dec 20023.94B+26.94%18.55%21.21B
FY200131 Dec 20013.10B-25.52%15.10%20.53B
FY200031 Dec 20004.16B+129.82%23.02%18.08B
FY199931 Dec 19991.81B-1.36%21.33%8.49B
FY199831 Dec 19981.84B-0.76%23.00%7.98B
FY199731 Dec 19971.85B-7.36%23.18%7.98B
FY199631 Dec 19962.00B+36.97%23.94%8.34B
FY199531 Dec 19951.46B+40.29%13.90%10.49B
FY199430 Jun 19951.04B-19.99%16.04%6.48B
FY199330 Jun 19941.30B+7.62%22.97%5.66B
FY199230 Jun 19931.21B+16.84%24.48%4.93B
FY199130 Jun 19921.03B+17.25%25.22%4.10B
FY199030 Jun 1991881.00M+9.17%25.93%3.40B
FY198930 Jun 1990807.00M+17.30%25.39%3.18B
FY198830 Jun 1989688.00M+18.42%26.77%2.57B
FY198730 Jun 1988581.00M+13.92%28.22%2.06B
FY198630 Jun 1987510.00M+27.50%29.29%1.74B
FY198530 Jun 1986400.00M—27.99%1.43B

Figures in GBP. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Income statement

Common questions about GSK's profit

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.